- Investors are gobbling up nano cap BG Medicine (BGMD +15.6%) today. Shares are up 16% on 6x normal volume.
- The current up trend began on December 12 after the company announced a 69% increase in Medicare reimbursement for its Gelectin-3 blood test.
- Since then, the firm announced positive results for the automated version of the test and met NASDAQ Capital Markets' listing requirements.
- Consensus revenue estimates for 2013 and 2014 are $4.1M and $6.2M, respectively.